

SEP 06 2005

S/N 10/729,276

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|-------------|--------------------------------------|-----------------|---------------|
| Applicant: | Haque et al. | Examiner: | Spivack, P.G. |
| Serial No.: | 10/729,276 | Group Art Unit: | 1614 |
| Filed: | December 3, 2003 | Docket No.: | 12695.13USD2 |
| Title: | TREATMENT OF CEREBROVASCULAR DISEASE | | |

CERTIFICATE UNDER 37 C.F.R. 1.6(d):

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on September 6, 2005.

By: _____

Name: _____

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it was originally submitted on March 3, 2004 prior to the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

Since this application was filed after June 30, 2003, a copy the U.S. Patent listed on the enclosed Form 1449 is not provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked

BEST AVAILABLE COPY


as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: September 6, 2005



Brian R. Dorn
Reg. No. 57,395
BRD/mls



Date Mailed: September 6, 2005

Sheet 1 of 1

| | | |
|---|--------------------------------|-----------------------------------|
| FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary) | Docket Number: 12695.13USD2 | Application Number: 10/729,276 |
| | Applicant: HAQUE ET AL. | |
| | Filing Date: 12/03/2003 | Group Art Unit: 1614 |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|--------------|------------|-------|-------|----------|----------------------------|
| EXAMINER INITIAL | DOCUMENT NO. | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | 6,339,085 | 01/15/2002 | Haque | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|--------------|------|---------|-------|----------|-------------|----|
| | DOCUMENT NO. | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | YES | NO |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|--|--|--|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

23552

PATENT TRADEMARK OFFICE

| | |
|---|-----------------|
| EXAMINER | DATE CONSIDERED |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant. | |

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Sheet 1 of 6

Date Mailed: June 14, 2001

| | | |
|--|--------------------------------|-----------------------------------|
| FORM 1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary) | Docket Number: 12595.13USU1 | Application Number: 09/820,199 |
| | Applicant: HAQUE ET AL. | |
| | Filing Date: 03/28/2001 | Group Art Unit: 1614 |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|--------------|------------|-------------------|-------|----------|----------------------------|
| EXAMINER INITIAL | DOCUMENT NO. | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| 2/8 | 3,206,463 | 09/14/1965 | Bectz | | | |
| | 3,910,921 | 10/07/1975 | Esanu | | | |
| | 3,987,177 | 10/19/1976 | Giudicelli et al. | | | |
| | 4,032,534 | 06/28/1977 | Chodkiewicz | | | |
| | 4,036,844 | 07/19/1977 | Thorne et al. | | | |
| | 4,053,607 | 10/11/1977 | Thorne et al. | | | |
| | 4,137,316 | 01/30/1979 | Esanu | | | |
| | 4,167,562 | 09/11/1979 | Evans | | | |
| | 4,361,570 | 11/30/1982 | Fid | | | |
| | 4,369,172 | 01/18/1983 | Scher et al. | | | |
| | 4,374,841 | 02/22/1983 | Descamps et al. | | | |
| | 4,515,771 | 05/07/1985 | Fino | | | |
| | 4,567,179 | 01/28/1986 | Lombardino | | | |
| | 4,569,938 | 02/11/1986 | Esanu | | | |
| | 4,569,939 | 02/11/1986 | Esanu | | | |
| | 4,581,363 | 04/08/1986 | Esanu | | | |
| | 4,605,741 | 08/12/1986 | Zagnoli et al. | | | |
| | 4,730,042 | 03/08/1988 | Hoge et al. | | | |
| | 4,735,950 | 04/05/1988 | Esanu | | | |
| | 4,735,956 | 05/05/1988 | Baldwin et al. | | | |
| V | 4,837,239 | 06/06/1989 | Benjamin et al. | | | |
| | 4,843,071 | 06/27/1989 | Hohenwarter | | | |
| | 4,962,121 | 10/09/1990 | Hamburger et al. | | | |
| | 5,001,115 | 03/19/1991 | Sloan | | | |
| | 5,053,396 | 10/01/1991 | Blass | | | |
| | 5,118,505 | 06/02/1992 | Keltinger | | | |
| | 5,130,324 | 07/14/1992 | Ulrich et al. | | | |
| | 5,132,115 | 07/21/1992 | Walter et al. | | | |

| | | | |
|---|--|-----------------|---------|
| EXAMINER | WILLIAM R. A. JARVIS PRIMARY EXAMINER | DATE CONSIDERED | 5/13/02 |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant. | | | |

Sheet 2 of 6

Data Mailed: June 14 2001

FORM 1449

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(attach several sheets if necessary)

Docket Number:

12695.15USU1

Application Number:

09/820,199

Applicant: HAQUE ET AL.

Filing Date: 03/28/2001

Group Art Unit: 1614

| | | | | | | | |
|-----------|------------|------------------|--|--|--|--|--|
| 5,210,083 | 05/11/1993 | Pfaffman | | | | | |
| 5,213,813 | 05/25/1993 | Kornacki et al. | | | | | |
| 5,254,597 | 10/19/1993 | Bucklin et al. | | | | | |
| 5,254,573 | 10/19/1993 | Sarfontein | | | | | |
| 5,272,165 | 12/21/1993 | Ulrich et al. | | | | | |
| 5,278,154 | 01/11/1994 | Lacoste et al. | | | | | |
| 5,288,716 | 02/22/1994 | Spock | | | | | |
| 5,326,757 | 07/05/1994 | Demopoulos | | | | | |
| 5,328,453 | 07/12/1994 | Sibalis | | | | | |
| 5,372,999 | 12/13/1994 | Schneider et al. | | | | | |
| 5,385,937 | 01/31/1995 | Stamler et al. | | | | | |
| 5,420,112 | 05/30/1995 | Lewis et al. | | | | | |
| 5,441,972 | 08/15/1995 | Ogata et al. | | | | | |
| 5,504,090 | 04/02/1996 | Neely | | | | | |
| 5,563,126 | 10/08/1996 | Allen et al. | | | | | |
| 5,569,459 | 10/29/1996 | Shlyankevich | | | | | |
| 5,569,648 | 10/29/1996 | Lewis et al. | | | | | |
| 5,631,271 | 05/20/1997 | Serfatina | | | | | |
| 5,633,228 | 05/27/1997 | Lewis et al. | | | | | |
| 5,648,335 | 07/15/1997 | Lewis et al. | | | | | |
| 5,728,684 | 03/17/1998 | Chong et al. | | | | | |
| 5,733,884 | 03/31/1998 | Burbul et al. | | | | | |
| 5,733,916 | 03/31/1998 | Neely | | | | | |
| 5,770,215 | 06/23/1998 | Moshaydi | | | | | |
| 5,795,873 | 08/18/1998 | Allen | | | | | |
| 5,804,163 | 09/08/1998 | Gibby et al. | | | | | |
| 5,804,594 | 09/08/1998 | Murad | | | | | |
| 5,833,998 | 11/10/1998 | Blodemann et al. | | | | | |
| 5,834,446 | 11/10/1998 | Dow et al. | | | | | |
| 5,840,683 | 11/24/1998 | Fujii et al. | | | | | |
| 5,847,008 | 12/08/1998 | Doebber et al. | | | | | |

EXAMINER

WILLIAM R. A. JARVIS

DATE CONSIDERED

5/13/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

Date Mailed: June 14, 2001

Sheet 3 of 6

| | | |
|---|--------------------------------|-----------------------------------|
| FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION <small>(File several sheets if necessary)</small> | Docket Number: 12695.13USU1 | Application Number: 09/820.199 |
| | Applicant: HAQUE ET AL. | |
| | Filing Date: 03/28/2001 | Group Art Unit: 1614 |

| | | | | | | |
|-----------|------------|-------------------|--|--|--|--|
| 5,858,017 | 01/12/1999 | Demopoulos et al. | | | | |
| 5,859,031 | 01/12/1999 | Adams et al. | | | | |
| 5,874,420 | 02/23/1999 | Pelleg | | | | |
| 5,874,443 | 02/23/1999 | Klely et al. | | | | |
| 5,888,514 | 03/30/1999 | Welsman | | | | |
| 5,944,020 | 08/31/1999 | Markov et al. | | | | |
| 6,043,299 | 03/28/2000 | Dballin et al. | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NO. | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|--------------|------------|---------|-------|----------|-------------|----|
| | | | | | | YRS | NO |
| | 431,350 | 01/14/1976 | BE | | | | X |
| | 863,754 | 05/29/1976 | BE | | | | X |
| | 361 183 | 04/30/1975 | CH | | | | X |
| | 1 958 226 | 05/27/1970 | DE | | | | X |
| | 37 05 549 A1 | 09/01/1988 | DE | | | | X |
| | 43 44 751 A1 | 06/20/1995 | DE | | | | X |
| | 24 61 742 A | 07/08/1976 | DT | | | | X |
| | 0 121 036 A1 | 10/10/1984 | EP | | | | |
| | 0 144 051 A2 | 06/12/1985 | EP | | | | |
| | 0 270 026 A2 | 06/08/1988 | EP | | | | |
| | 0 416 248 A2 | 03/13/1991 | EP | | | | |
| | 0 891 719 A1 | 01/20/1999 | EP | | | | |
| | 846,376 | 03/26/1941 | FR | | | | X |
| | 1,323,941 | 12/15/1963 | FR | | | | X |
| | 5,352 M | 12/26/1967 | FR | | | | X |
| | 6,453 M | 12/16/1968 | FR | | | | X |
| | 1,579,544 | 08/29/1969 | FR | | | | X |
| | 2,101,010 | 03/31/1972 | FR | | | | X |
| | 2,255,883 | 07/25/1975 | FR | | | | X |
| | 2,428,640 | 01/11/1980 | FR | | | | X |

| | |
|---|----------------------------|
| EXAMINER WILLIAM R. A. JARVIS PRIMARY EXAMINER | DATE CONSIDERED 5/13/02 |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant. | |

Sheet 4 of 6

Date Mailed: June 14 2001

| | | |
|--|---------------------------------|-----------------------------------|
| FORM 1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (attach several sheets if necessary) | Decklet Number: 12695.13USU1 | Application Number: 09/820,199 |
| | Applicant: HAQUE ET AL. | |
| | Filing Date: 03/28/2001 | Group Art Unit: 1614 |

| | | | | | | | | | |
|-------------|------------|-----|--|--|--|--|--|----------|---|
| 013 939 | 12/22/1965 | GB | | | | | | | |
| 1,172,800 | 12/03/1969 | GB | | | | | | | |
| 1 201 014 | 08/05/1970 | GB | | | | | | | |
| 1 297 080 | 11/22/1972 | GB | | | | | | | |
| 1 360 536 | 07/17/1974 | GB | | | | | | | |
| 1 493 993 | 12/07/1977 | GB | | | | | | | |
| 2 254 556 A | 10/14/1992 | GB | | | | | | | |
| 5,801 M | 03/28/1968 | FR | | | | | | | X |
| 2 034 539 | 12/11/1970 | FR | | | | | | | X |
| 48-21959 | 07/02/1973 | JP | | | | | | | X |
| 54-17130 | 02/08/1979 | JP | | | | | | | X |
| WO 83/00085 | 01/20/1983 | PCT | | | | | | | |
| WO 91/19500 | 12/28/1991 | PCT | | | | | | Abstract | |
| WO 94/18965 | 09/01/1994 | PCT | | | | | | | |
| WO 99/03365 | 01/28/1999 | PCT | | | | | | | |
| WO 99/53928 | 10/23/1999 | PCT | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Periodic Pages, Etc.)

| | |
|-----|---|
| 250 | Aybak, M. et al., "Effect of Oral Pyridoxine Hydrochloride Supplementation on Arterial Blood Pressure in Patients with Essential Hypertension". <i>Drug Res.</i> , Vol. 45, No. 12, pp. 1271-1273 (1995). |
| | "B Vitamins May Cut Heart Disease Risk", <i>Harvard Health Letter</i> , 1 page (1998) |
| | Baliga, R. et al., "Hyperhomocysteinemia in Type 2 Diabetes Mellitus: Cardiovascular Risk Factors and Effect of Treatment with Folate Acid and Pyridoxine", <i>Endocrine Practices</i> , Vol. 6, No. 6, pp. 435-441 (November/December 2000). |
| | Bernick, S., "Homocysteine: A Cardiovascular Risk Factor Worth Considering", http://www.quickwatch.com/03HealthPromotion/homocysteine.html , 2 pages (©1997) |
| | Bornstein, A., "Vitamin B6 in Clinical Neurology", <i>Annals of New York Academy of Sciences</i> , Vol. 585, pp. 250-260 (1990) |
| | Borger, A.R. et al., "Dose response, crossing, and differential fiber vulnerability in human toxic neuropathy: A prospective study of pyridoxine neurotoxicity", <i>Neurology</i> , Vol. 42, No. 7, pp. 1367-1370 (July 1992) |
| | Bhagavan, H. et al., "Effect of Postweanling Pyridoxine Deficiency on Growth and Concentration of the Coenzyme Pyridoxal-5-phosphate in Heart, Kidneys, Lungs, and Adrenals in Rats", <i>Pediat. Res.</i> , Vol. 10, pp. 730-732 (1976). |
| | Dode, W. et al., "Pyridoxal-5-Phosphate and Pyridoxal Biokinetics in Male Wistar Rats Fed Graded Levels of Vitamin B-6", <i>J. Nutr.</i> , Vol. 121, No. 11, pp. 1738-1745 (November 1991) |
| | Chasan-Taber, L. et al., "A Prospective Study of Folate and Vitamin B6 and Risk of Myocardial Infarction in US Physicians", <i>Journal of the American College of Nutrition</i> , Vol. 15, No. 2, pp. 136-143 (April 1996) |

| | | | |
|---|----------------------|-----------------|---------|
| EXAMINER | WILLIAM R. A. JARVIS | DATE CONSIDERED | 5/13/02 |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not in conformance of this form for next communication to the Applicant. | | | |

06/10/02 12:00 FAX 813 238 2485

RIDOUT & MAYBEE

014

Sheet 5 of 6

Date Mailed: June 14 2001

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

12695.13USU1

Application Number:

09/820,199

Applicant: HAQUE ET AL.

Filing Date: 03/28/2001

Group Art Unit: 1614

- Cho, Y. et al., "In Vivo Evidence for a Vitamin B-6 Requirement in Carnitine Synthesis", *J. Nutr.*, Vol. 120, pp. 258-265 (1990)
- "Computer Generated Search Reports", 70 pages (May 1999)
- Ellis, J. et al., "Prevention of Myocardial Infarction by Vitamin B6", *Res. Commun. Molec. Pathol. Pharmacol.*, Vol. 89, No. 2, pp. 208-220 (August 1995)
- Folsom, A. et al., "Clinical Investigation and Reports: Prospective Study of Coronary Heart Disease Incidence in Relation to Fasting Total Homocysteine, Related Genetic Polymorphisms, and B Vitamins: The Atherosclerosis Risk in Communities (ARIC) Study", *Circulation*, Vol. 98, pp. 204-210 (July 21, 1998).
- Harada, K. et al., "Studies on Vitamin B6. (IV) Behavior of Pyridoxal Acylates in the Body After Parenteral Administration", *Vitamin Journal of the Vitamin Society of Japan*, Vol. 45, No. 2, pp. 69-75 (February 1972)
- Hatchcock, J., "Vitamins and minerals: efficacy and safety", *Am J Clin Nutr*, Vol. 66, pp. 421 - 437 (1997)
- Hoover, D.M. et al., "Ultrastructural Lesions of Pyridoxine Toxicity in Beagle Dogs", *Vet. Pathol.*, Vol. 18, pp. 769-777 (1981)
- Kok, F. et al., "Low Vitamin B6 Status in Patients with Acute Myocardial Infarction", *Am. J. Cardiol.*, Vol. 63, pp. 513-516 (March 1, 1989)
- Korynyk et al. Schiff Bases of Pyridoxal: Their Structure and the Stabilization of their Ring-Chain Tautomeric Forms by Acylation, *Tetrahedron*, 26 (23), 5415-25, 1982.
- Krinks, G. et al., "Pyridoxine Megavitaminosis: An Analysis of the Early Changes Induced with Massive Doses of Vitamin B6 in Rat Primary Sensory Neurons", *J. Neuropathol. Exp. Neurol.*, Vol. 44, No. 7, pp. 117-129 (March 1985)
- Kubyshkin, V. et al., "Comparative characteristics of the arrhythmic syndrome and the possibility for its coenzyme correction in dilated and hypertrophic cardiomyopathy", *Abstracts*, 1 pg. (1989).
- Lai, K. et al., "Hypertensive action of 5-HT receptor agonists in the vitamin B6-deficient hypertensive rat", *Eur. J. Pharmacol.*, Vol. 234, Nos. 2/3, pp. 183-189 (April 1993)
- Lai, K. et al., "Calcium channels in vitamin B6 deficiency-induced hypertension", *Journal of Hypertension*, Vol. 11, No. 12, pp. 1357-1362 (December 1993)
- Lai, K. et al., "The effect of vitamin B6 on the systolic blood pressure of rats in various animal models of hypertension", *Journal of Hypertension*, Vol. 14, No. 3, pp. 353-363 (March 1996)
- Levy, H. et al., "Pyridoxine Deficiency in Congestive Heart Failure", *P.S.E.B.M.*, Vol. 101, pp. 617-621 (1959)
- Mesoro, M. et al., "Changes in Plasma Pyridoxal Phosphate (PLP) in Diabetic (D), Hypertensive (HTN) and Hypertensive-diabetic (HTN-D) Men Fed A Constant Vitamin B-6 (06) Diet", *Source Unknown*, pp. 1254 (1990).
- Markov, A. et al., "Hemodynamic, electrocardiographic, and metabolic effects of fructose diphosphate on acute myocardial ischemia", *American Heart Journal*, Vol. 100, No. 5, pp. 639 - 646 (November 1980)
- Mendelsohn, A. et al., "Hemodynamic and Clinical Effects of Oral Levodopa in Children With Congestive Heart Failure", *JACC*, Vol. 30, No. 1, pp. 237-242 (July 1997).
- Merrill, Jr. et al. A. et al., "Diseases associated with defects in vitamin B6 metabolism or utilization", *Ann. Rev. Nutr.*, Vol. 7, pp. 137-156 (1987)
- Mulveney, D. et al., "Electrocardiographic changes in vitamin B6 deficient rats", *Cardiovascular Research*, Vol. 13, pp. 506-513 (1979).
- Omenn, G. et al., "Preventing Coronary Heart Disease", *Circulation*, Vol. 97, pp. 421-424 (1998)
- Paulose, C. et al., "Sympathetic Stimulation and Hypertension in the Pyridoxine-Deficient Adult Rat", *Hypertension*, Vol. 11, No. 4, pp. 387-391 (April 1988)

EXAMINER

WILLIAM R. A. JARVIS

DATE CONSIDERED

5/13/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

06/10/02 12:01 FAX 613 236 2485

RIDOUT & MAYBEE

Sheet 6 of 6

Date Mailed: June 14, 2001

| | | |
|--|--------------------------------|-----------------------------------|
| FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary) | Docket Number: 12695.13USU1 | Application Number: 09/820,199 |
| | Applicant: HAQUE ET AL. | |
| | Filing Date: 03/28/2001 | Group Art Unit: 1614 |

| | |
|--|--|
| | Rao, R. et al., "Failure of Pyridoxine to Improve Glucose Tolerance in Diabetics", <i>Journal of Clinical Endocrinology & Metabolism</i> , Vol. 50, No. 1, pp. 198-200 (January 1980). |
| | Rimm, E. et al., "Folate and Vitamin B6 From Diet and Supplements in Relation to Risk of Coronary Heart Disease Among Women", <i>JAMA</i> , Vol. 279, No. 5, pp. 359-364 (February 4, 1998) |
| | Sakumagi, T. et al., "The Synthesis of Long Chain Fatty Acid Derivatives of the Vitamin B6 Group", <i>J. Am. Chem. Soc.</i> , Vol. 78, pp. 839-842 (February 20, 1956) |
| | Schulz, R. et al., "Differential changes in left and right ventricular adenylyl cyclase activities in congestive heart failure", <i>The American Physiological Society</i> , Vol. 272, No. 2, Part 2 of Two Parts, pp. H884 - H893 (February 1997) |
| | Sethi, R. et al., "Inotropic Responses to Isoproterenol in Congestive Heart Failure Subsequent to Myocardial Infarction in Rats", <i>Journal of Cardiac Failure</i> , Vol. 1, No. 5, pp. 391 - 399 (December 1995) |
| | Takuma, Y. et al., "Combination Therapy of Infantile Spasms With High-Dose Pyridoxal Phosphate and Low-Dose Carbamazepine", <i>Journal of Child Neurology</i> , Vol. 11, No. 1, pp. 35-40 (January 1996) |
| | Tanaka, T. et al., "Pyridoxine Derivatives", <i>Chemical Abstracts</i> , Vol. 62, No. 12, 1 page (June 7, 1965) |
| | Trozhko, D. et al., "P2 purinoceptor antagonist properties of pyridoxal-S-phosphate", <i>Eur. J. Pharmacol.</i> , Vol. 259, No. 3, pp. 295-300 (July 11, 1994) |
| | Vanderjeer, D. et al., "Vitamin B6 Status in a Healthy Elderly Population", <i>Annals New York Academy of Sciences</i> , pp. 562 - 564 (1990) |
| | Verhoef, P. et al., "A Common Mutation in the Methylene-tetrahydrofolate Reductase Gene and Risk of Coronary Heart Disease: Results Among U.S. Men", <i>JACC</i> , Vol. 32, No. 2, pp. 353 - 359 (August 1998) |
| | Verhoef, P. et al., "Homocysteine Metabolism and Risk of Myocardial Infarction: Relation with Vitamins B6, B12, and Folate", <i>Am. J. Epidemiol.</i> , Vol. 143, No. 9, pp. 843-859 (May 1, 1996) |
| | Vennart, W.J.H. et al., "Vitamin B6 and coronary artery disease. Epidemiological observations and case studies", <i>Atherosclerosis</i> , Vol. 63, pp. 225-238 (February 1987) |
| | Vidrio, H., "Interaction with Pyridoxal as a Possible Mechanism of Hydralazine Hypotension", <i>Journal of Cardiovascular Pharmacology</i> , Vol. 15, pp. 150-156 (1990) |
| | Visconti, V. et al., "Über einige Derivate des Pyridoxals", <i>Helvetica Chimica Acta</i> , Vol. 34, No. 296, pp. 2438-2439 (1951) |
| | Windbank, A., "Neurotoxicity of Pyridoxine Analogs is Related to Coenzyme Structure", <i>Neurochemical Pathology</i> , Vol. 9, pp. 159-167 (1985) |
| | Yam, A. et al., "Effect of vitamin B6 on lenses of diabetic rats", <i>Indian Journal of Experimental Biology</i> , Vol. 36, pp. 1269-1272 (December 1998) |
| | Zamploni, J. et al., "The utilization of intravenously infused pyridoxine in humans", <i>Clinica Chimica Acta</i> , Vol. 229, Nos. 1, 2, pp. 27-36 (September 1994) |

EXAMINER

WILLIAM R. A. JARVIS

DATE CONSIDERED

5/13/02

PRIMARY EXAMINER

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not in conformance to the Applicant.

06/10/02 12:01 FAX 613 236 2485

RIDOUT & MAYBEE

016

006

RIDOUT&MAYBEE

PAGE 1 of 2

Form PTO-1449
(Rev. 9-94)U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
29399-0014SERIAL NO.
US 09/820,199

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

APPLICANT
Medicare International Inc.FILING DATE
3/28/2001GROUP
1614

(Use several sheets if necessary)

U. S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|------------------|-----------------|------|------|-------|----------|----------------------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|-----------------|------|---------|-------|----------|-------------|----|
| | | | | | YES | NO |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

OTHER INFORMATION (including author, title, date, pertinent pages, etc.)

Volpe J. J., "Management of Neonatal Seizures", *Critical Care Medicine*, Vol. 3, No. 1, pp. 43 to 46 (1977 Jan-Feb)Brett H. et al., "New Aspects to the Treatment of Cerebral Ischemia", *Minor Medical/Intake Wochenschrift*, Vol. 125, No. 45, pp. 646 to 650 (1975)

WILLIAM R. A. JARVIS

DATE CONSIDERED

5/16/02

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.